The mission of our conference is to explore and address the issues surrounding early diagnosis of lung cancer, how to optimize early treatment, and to expand practice-relevant research to medical and scientific communities in the U.S. and abroad. This is the 40th conference in a series of conferences that began in 1999 in New York City and, since, has been hosted in China, Europe, Israel, Japan, and coast-to-coast in the United States.
The Early Lung Cancer Action Program (ELCAP) screening effort began in 1992 and evolved into the International Early Lung Cancer Action Program (I-ELCAP). By providing training and the ELCAP Management System to those interested in screening, these programs expanded worldwide. The resulting data and analyses provide new diagnostic knowledge that is being continually integrated into the screening regimen so that it remains state-of-the-art. The screening advances are addressed at every conference. In addition, the Early Lung Cancer Research on Treatment (IELCART) uses the power of the prospective cohort design to accumulate data on treatment delivered for Stage I lung cancer and to address questions about optimal treatment. The IELCART research goal is to maximize the benefit of screening by determining optimal treatment for these Stage I lung cancer patients. Finally, the newest focus of research at this conference is interstitial lung disease (ILD) as this disease often affects older smokers. Following the same research paradigms as I-ELCAP & IELCART, an ILD registry has been developed and collaborating sites have been recruited.
Please register for the conference here.
For any questions about the conference, please contact Maryanne Rubacky (e-mail or 212-241-2325).